https://orcid.org/0000-0002-5465-1648
Figures & data
Table 1. Second- and subsequent-line treatments of interest included in this analysis.
Figure 1. Study design.
*A LoT is defined by the first 30 days of treatment. A gap of 60 days between treatments advances the LoT, even if the same regimen is received on either side of the gap; †Follow-up refers to the time period during which healthcare costs were recorded, from first administration until the first of the following: patients begin a new regimen (defined by receipt of a new regimen given after a treatment gap of 60 days, or the addition/substitution of new agents ≥30 days after starting initial therapy [adapted from Yang X, et al. 2021Citation27]), or it had been 180 days since they last received treatment, or end of clinical follow-up/date availability.
LoT, line of therapy; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone; Rx, start of systemic drug therapy regimen.
![Figure 1. Study design.*A LoT is defined by the first 30 days of treatment. A gap of 60 days between treatments advances the LoT, even if the same regimen is received on either side of the gap; †Follow-up refers to the time period during which healthcare costs were recorded, from first administration until the first of the following: patients begin a new regimen (defined by receipt of a new regimen given after a treatment gap of 60 days, or the addition/substitution of new agents ≥30 days after starting initial therapy [adapted from Yang X, et al. 2021Citation27]), or it had been 180 days since they last received treatment, or end of clinical follow-up/date availability.LoT, line of therapy; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone; Rx, start of systemic drug therapy regimen.](/cms/asset/55e6f576-709c-4f57-81ff-810f23787272/ijme_a_2349472_f0001_c.jpg)
Figure 2. Distribution of R/R DLBCL therapies received across LoTs.
*Included selinexor and ibrutinib. †Included other regimens that were not among the selected treatments of interest; ‡Included patients for whom no treatment was identified during the study period (e.g. due to patient death, change in insurance plan, or lost to follow-up).
CAR-T, chimeric antigen receptor T-cell therapy; DLBCL, diffuse large B-cell lymphoma; LoTs, lines of therapy; R/R, relapsed refractory; SCT, stem cell transplant.
Table 2. Baseline demographics and clinical characteristics according to LoT.
Figure 3. Overall PPPM costs by LoT and HCRU category.
Costs shown are means (SD).
ER, emergency room; HCRU, healthcare resource utilization; LoT, line of therapy; PPPL, per-patient-per-line; PPPM, per-patient-per-month; SD, standard deviation; USD, United States dollar.
